| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.1 | 0.03 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.34 | 0.03 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.096 | 0.04 |